-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Solid Tumor Drug Details: NKTR-255 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rulonilimab in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rulonilimab in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rulonilimab in Hepatocellular Carcinoma Drug Details: F-520 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cisplatin + Vinblastine Sulphate) in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cisplatin + Vinblastine Sulphate) in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cisplatin + Vinblastine Sulphate) in Glioblastoma Multiforme (GBM)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacmilimab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacmilimab in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacmilimab in Gastric Cancer Drug Details: CX-072 is under development for...
-
Company Insights
Innovation and Patenting activity of GB Group PLC Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of GB Group PLC Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rucaparib Camsylate in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rucaparib Camsylate in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rucaparib Camsylate in Solid Tumor Drug Details: Rucaparib camsylate (Rubraca) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-1211 in Liver Cirrhosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-1211 in Liver Cirrhosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GB-1211 in Liver Cirrhosis Drug Details: GB-1211 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-263 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-263 in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GB-263 in Esophageal Cancer Drug Details:GB-263 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-263 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-263 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GB-263 in Solid Tumor Drug Details:GB-263 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-5013 in Esophageal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GB-5013 in Esophageal Cancer Drug Details:GB-5013 is under development for the treatment of gastric cancer, adenocarcinoma...